human adenovirus type 5 encoding HPV-16 E6/E7 vaccine IBRX-042

A cancer vaccine composed of an adenovirus type 5 (Ad5) vector that encodes for the viral oncoproteins E6 and E7 derived from human papillomavirus serotype 16 (HPV-16; HPV16), with potential immunomodulating and antineoplastic activities. Upon administration, hAd5 encoding HPV-16 E6/E7 vaccine IBRX-042 induces expression of the HPV-16 E6/E7 proteins, which stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL)-mediated response against tumor cells expressing HPV-16 E6 and E7. Oncoproteins E6 and E7 play a key role in the development of various malignancies.